Test ID AD2 PrecivityAD2, Plasma
Ordering Guidance
This blood test is intended for use in adults aged 40 years and older who present with signs or symptoms of cognitive impairment undergoing evaluation for Alzheimer disease or other forms of cognitive decline. The test is not intended as a screening or stand-alone diagnostic test.
Shipping Instructions
1. Specimens must be shipped frozen on dry ice.
2. Place labeled aliquot tubes inside a larger tube or vial for transport.
Specimen Required
Supplies: Screw cap micro tube, 2 mL, PCR Performance Tested, Low protein-binding (T983)
Collection Container/Tube: 10 mL Purple top (K2-EDTA)
Submission Container/Tube: Two 2-mL screw cap micro tubes
Specimen Volume: 3 mL Plasma in 2 tubes, each containing 1.5 mL plasma
Collection Instructions:
1. Label two 2-mL screw-cap micro tubes.
2. Within 2 hours of collection, centrifuge and aliquot 1.5 mL of plasma into each labeled micro tube.
3. Freeze plasma (no longer than 2 hours after collection) at or below -20° C.
Note: If plasma sample is not being shipped on the day of collection/processing, the sample needs to be stored at -80° C.
Useful For
Assisting in the evaluation of adults aged 40 years and older, who present with signs or symptoms of cognitive impairment undergoing evaluation for Alzheimer disease or other forms of cognitive decline
This test is not intended for use as a screening or stand-alone diagnostic test. The safety and effectiveness of the PrecivityAD2 test have not been established for predicting development of dementia or other neurologic conditions, or for monitoring responses to therapies.
Method Name
Immunoprecipitation/Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
Reporting Name
PrecivityAD2Specimen Type
PlasmaSpecimen Minimum Volume
See Specimen Required
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Plasma | Frozen | |
Reference Values
Amyloid Probability Score 2 (APS2) (range of 0-100):
Positive
>66.5 is consistent with brain amyloid pathology
Likely Positive
>27.5 to < 66.5 is likely consistent with brain amyloid pathology
Negative
<27.5 is not consistent with brain amyloid pathology
APS2 results are reported as whole numbers from 0-100. The reporting ranges shown above are based on the APS2 cut points specified in the FDA-cleared PrecivityAD2 labeling.
Day(s) Performed
Monday through Friday
Report Available
13 days post sample receipt from MCLPerforming Laboratory
C2N Diagnostics LLCTest Classification
This test has been cleared by the U.S. Food and Drug Administration (FDA) under 510(k) K253240 and is performed according to the FDA-cleared labeling at C2N Diagnostics Laboratory. For prescription use only.CPT Code Information
0503U
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| AD2 | PrecivityAD2 | Not Provided |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| PD2A | Amyloid Probability Score | Not Provided |
| PD2B | APS2 Result | Not Provided |
| PD2C | Interpretation | Not Provided |
| PD2D | Indication for Use of the Test | Not Provided |
| PD2E | Test Description and Clinical Performance | Not Provided |
| PD2F | Limitations | Not Provided |
| PD2G | Report Comment | Not Provided |
| PD2H | Performing Site | Not Provided |